Logo image of OTRK

ONTRAK INC (OTRK) Stock Fundamental Analysis

NASDAQ:OTRK - Nasdaq - US6833734014 - Common Stock - Currency: USD

1.47  -0.06 (-3.77%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to OTRK. OTRK was compared to 102 industry peers in the Health Care Providers & Services industry. OTRK may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, OTRK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OTRK had negative earnings in the past year.
In the past year OTRK has reported a negative cash flow from operations.
In the past 5 years OTRK always reported negative net income.
In the past 5 years OTRK always reported negative operating cash flow.
OTRK Yearly Net Income VS EBIT VS OCF VS FCFOTRK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -445.78%, OTRK is not doing good in the industry: 97.06% of the companies in the same industry are doing better.
OTRK has a worse Return On Equity (-1752.70%) than 85.29% of its industry peers.
Industry RankSector Rank
ROA -445.78%
ROE -1752.7%
ROIC N/A
ROA(3y)-265.11%
ROA(5y)-172.32%
ROE(3y)-706.96%
ROE(5y)-452.52%
ROIC(3y)N/A
ROIC(5y)N/A
OTRK Yearly ROA, ROE, ROICOTRK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

With an excellent Gross Margin value of 57.60%, OTRK belongs to the best of the industry, outperforming 81.37% of the companies in the same industry.
In the last couple of years the Gross Margin of OTRK has grown nicely.
The Profit Margin and Operating Margin are not available for OTRK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y8.5%
OTRK Yearly Profit, Operating, Gross MarginsOTRK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

OTRK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OTRK has been increased compared to 1 year ago.
The number of shares outstanding for OTRK has been increased compared to 5 years ago.
OTRK has a worse debt/assets ratio than last year.
OTRK Yearly Shares OutstandingOTRK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
OTRK Yearly Total Debt VS Total AssetsOTRK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -44.83, we must say that OTRK is in the distress zone and has some risk of bankruptcy.
OTRK's Altman-Z score of -44.83 is on the low side compared to the rest of the industry. OTRK is outperformed by 94.12% of its industry peers.
A Debt/Equity ratio of 2.05 is on the high side and indicates that OTRK has dependencies on debt financing.
OTRK's Debt to Equity ratio of 2.05 is on the low side compared to the rest of the industry. OTRK is outperformed by 74.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z -44.83
ROIC/WACCN/A
WACC6.17%
OTRK Yearly LT Debt VS Equity VS FCFOTRK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

OTRK has a Current Ratio of 0.72. This is a bad value and indicates that OTRK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.72, OTRK is not doing good in the industry: 85.29% of the companies in the same industry are doing better.
OTRK has a Quick Ratio of 0.72. This is a bad value and indicates that OTRK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of OTRK (0.72) is worse than 78.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.72
OTRK Yearly Current Assets VS Current LiabilitesOTRK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

OTRK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.41%.
Looking at the last year, OTRK shows a very negative growth in Revenue. The Revenue has decreased by -21.03% in the last year.
Measured over the past years, OTRK shows a very negative growth in Revenue. The Revenue has been decreasing by -20.93% on average per year.
EPS 1Y (TTM)-61.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-21.03%
Revenue growth 3Y-49.48%
Revenue growth 5Y-20.93%
Sales Q2Q%-24.74%

3.2 Future

OTRK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.54% yearly.
Based on estimates for the next years, OTRK will show a very strong growth in Revenue. The Revenue will grow by 65.61% on average per year.
EPS Next Y45.86%
EPS Next 2Y27.35%
EPS Next 3Y26.88%
EPS Next 5Y15.54%
Revenue Next Year48.09%
Revenue Next 2Y51.63%
Revenue Next 3Y58.54%
Revenue Next 5Y65.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OTRK Yearly Revenue VS EstimatesOTRK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
OTRK Yearly EPS VS EstimatesOTRK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OTRK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OTRK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTRK Price Earnings VS Forward Price EarningsOTRK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTRK Per share dataOTRK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

OTRK's earnings are expected to grow with 26.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.35%
EPS Next 3Y26.88%

More info and screens

0

5. Dividend

5.1 Amount

OTRK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONTRAK INC

NASDAQ:OTRK (5/30/2025, 8:24:47 PM)

1.47

-0.06 (-3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-20 2025-05-20/amc
Earnings (Next)08-06 2025-08-06
Inst Owners15.07%
Inst Owner Change539.84%
Ins Owners0.03%
Ins Owner Change0%
Market Cap6.20M
Analysts82.86
Price Target4.08 (177.55%)
Short Float %0.53%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.61%
Min EPS beat(2)-30.46%
Max EPS beat(2)1.23%
EPS beat(4)1
Avg EPS beat(4)-31.68%
Min EPS beat(4)-86.27%
Max EPS beat(4)1.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-20.84%
Min Revenue beat(2)-41.84%
Max Revenue beat(2)0.16%
Revenue beat(4)1
Avg Revenue beat(4)-13.1%
Min Revenue beat(4)-41.84%
Max Revenue beat(4)0.16%
Revenue beat(8)1
Avg Revenue beat(8)-24.66%
Revenue beat(12)1
Avg Revenue beat(12)-23.76%
Revenue beat(16)4
Avg Revenue beat(16)-16.46%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.63
EYN/A
EPS(NY)-2.89
Fwd EYN/A
FCF(TTM)-3.1
FCFYN/A
OCF(TTM)-3.06
OCFYN/A
SpS2.41
BVpS1.1
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -445.78%
ROE -1752.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.6%
FCFM N/A
ROA(3y)-265.11%
ROA(5y)-172.32%
ROE(3y)-706.96%
ROE(5y)-452.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y8.5%
F-Score2
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.45%
Cap/Sales 1.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.72
Altman-Z -44.83
F-Score2
WACC6.17%
ROIC/WACCN/A
Cap/Depr(3y)14.24%
Cap/Depr(5y)49.22%
Cap/Sales(3y)3.95%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y45.86%
EPS Next 2Y27.35%
EPS Next 3Y26.88%
EPS Next 5Y15.54%
Revenue 1Y (TTM)-21.03%
Revenue growth 3Y-49.48%
Revenue growth 5Y-20.93%
Sales Q2Q%-24.74%
Revenue Next Year48.09%
Revenue Next 2Y51.63%
Revenue Next 3Y58.54%
Revenue Next 5Y65.61%
EBIT growth 1Y-8.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y31.42%
EBIT Next 5Y30.92%
FCF growth 1Y32.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.01%
OCF growth 3YN/A
OCF growth 5YN/A